SR

Suman Rani

Active Director Director DIN 08026611
DIN 08026611 First appointment Jan 2018 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2018
Shareholding value •••• Premium profile

About Suman Rani

Data last updated:

Suman Rani is a Director at Kratom Pharma Private Limited (since 2018). The company operates in Chemicals. Kratom Pharma Private Limited reported revenue of ₹23.2 Lakh (FY 2024).

DIN 08026611
Primary Designation Director
Industry Chemicals
First Appointment 18 Jan 2018
Oldest Company Age 8 yrs
Largest company Kratom Pharma Private Limited · ₹23.2 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Kratom Pharma Private Limited U24239UP2018PTC100476
Director18 Jan 20182018₹23.2 Lakh (FY 2024)Active

Board colleagues of Suman Rani

NameDINCompanyDesignation
Ram Nath Ram08026635Kratom Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Kratom Pharma Private Limited
Premium access

Shareholding and investment profile for Suman Rani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suman Rani

Suman Rani currently holds 1 directorship: Kratom Pharma Private Limited (Director, since 18 Jan 2018, revenue ₹23.2 Lakh (FY 2024)).

Suman Rani was first appointed on 18 Jan 2018 as Director at Kratom Pharma Private Limited.

The current boards of Suman Rani's companies include Ram Nath Ram (Kratom Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available